Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. IGEA Pharma N.V.
  6. News
  7. Summary
    IGPH   NL0012768675

IGEA PHARMA N.V.

(IGPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IGEA Pharma N.V.: GBC AG TO START EQUITY COVERAGE OF IGEA PHARMA

10/04/2021 | 05:56pm EST

EQS Group-Ad-hoc: IGEA Pharma N.V. / Key word(s): Agreement/Research Update IGEA Pharma N.V.: GBC AG TO START EQUITY COVERAGE OF IGEA PHARMA 04-Oct-2021 / 23:55 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

GBC AG TO START EQUITY COVERAGE OF IGEA PHARMA

Hoofddorp, the Netherlands, 04October 2021. IGEA Pharma N.V. (SIX: IGPH) today announced that GBCAG (www.gbc-ag.de/) will begin a full-coverage equity research on the Company.

Following the successful closing of the business combination ("Combination") with Blue Sky Natural Resources LTD ("BSNR"), and the start of trading of the new combined entity on the 27^th of September, Igea Pharma has agreed to a full-coverage service with GBC, a German based investment research firm that focuses on small and medium enterprises both listed and non-listed with a company value of between 10 and 500 million euros.

The IGEA Pharma CEO, Vincenzo Moccia said "We are thrilled to start this cooperation with GBC, which counts on a solid track record for a range of investment banking services. We are convinced that the equity coverage will strengthen the market appeal on the Igea stock".

Manuel Hölzle, CEO of GBC commented "At GBC we are continuously looking for appealing, innovative and fast growing companies and we believe that Igea has a significant potential to become a product and technology leader in its industry thanks to the recently completed business combination".

***

About IGEA IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline. The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl Contacts Giovanna Puppo della Gherardesca, Chairman, puppo@igearesearch.com Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igearesearch.com

Disclaimer This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.

-----------------------------------------------------------------------------------------------------------------------

End of ad hoc announcement

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      IGEA Pharma N.V. 
              Siriusdreef 17 
              2123 WT Hoofddorp 
              Netherlands 
Phone:        +31 23 568 9494 
E-mail:       info@igearesearch.com 
Internet:     www.igeapharma.nl 
ISIN:         NL0012768675 
Listed:       Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange 
EQS News ID:  1238191 
 
End of Announcement EQS Group News Service 
=------------ 

1238191 04-Oct-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1238191&application_name=news

(END) Dow Jones Newswires

October 04, 2021 17:55 ET (21:55 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
IGEA PHARMA N.V. 3.23% 0.32 Delayed Quote.-42.59%
WT GROUP HOLDINGS LIMITED -2.22% 0.044 End-of-day quote.-60.00%
All news about IGEA PHARMA N.V.
11/25IGEA PHARMA N : GBC Research report IGEA Pharma N.V.
PU
11/25IGEA PHARMA N : GBC AG Publishes initial equity research report with buy recommendation an..
PU
11/25IGEA PHARMA N.V. : Gbc ag publishes initial equity research report with buy recommendation..
EQ
10/04IGEA PHARMA N : GBC AG to start equity coverage of IGEA Pharma
PU
10/01IGEA PHARMA N : H1 Loss Narrows on Gains From Financial Liabilities, Sale of Assets
MT
09/30IGEA Pharma N.V. Reports Earnings Results for First Half 2021
CI
09/30Igea Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
09/30IGEA PHARMA N : discloses its half-2021 financials
PU
09/27IGEA PHARMA N : has been granted the listing of the new shares from SIX Exchange Regulatio..
PU
09/08IGEA PHARMA N : to submit the listing prospectus to the SIX following the business combina..
PU
More news
Financials
Sales 2021 0,14 M 0,16 M 0,16 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 99,5 M 113 M 113 M
Capi. / Sales 2021 711x
Capi. / Sales 2022 1,95x
Nbr of Employees 2
Free-Float 82,3%
Chart IGEA PHARMA N.V.
Duration : Period :
IGEA Pharma N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,30 €
Average target price 1,05 €
Spread / Average Target 253%
Managers and Directors
Vicenzo Moccia Chairman-Management Board
Sector and Competitors
1st jan.Capi. (M$)
IGEA PHARMA N.V.-42.59%113
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.74.02%23 186
BIOMÉRIEUX8.49%16 984
10X GENOMICS, INC.7.92%16 136
DIASORIN S.P.A.8.82%11 415
NATERA, INC.-8.10%8 627